Compare PRGO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | URGN |
|---|---|---|
| Founded | 1887 | 2004 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2013 | 2016 |
| Metric | PRGO | URGN |
|---|---|---|
| Price | $16.23 | $26.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $18.00 | ★ $60.71 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $800,000.00 | ★ $1,128,000.00 |
| Revenue This Year | N/A | $190.44 |
| Revenue Next Year | N/A | $69.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.23 | $16.50 |
| 52 Week High | $17.02 | $50.81 |
| Indicator | PRGO | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 27.59 |
| Support Level | $9.93 | $23.51 |
| Resistance Level | $16.79 | $27.76 |
| Average True Range (ATR) | 0.70 | 2.05 |
| MACD | -0.02 | -0.35 |
| Stochastic Oscillator | 60.79 | 13.91 |
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.